Skip to main content
. Author manuscript; available in PMC: 2017 Feb 2.
Published in final edited form as: Radiat Res. 2016 Feb 2;185(2):169–181. doi: 10.1667/RR14285.1

FIG. 6.

FIG. 6

Single doses or fractionated doses combined with cisplatin in the TTA + CSC reverts the expression profile of proteins and cytokines associated with the invasive phenotype in lung cancer. Panel A: Quantification of pixel intensity as a measure of protein expression from TTA + CSC lysates 5 days after treatment incubated with the human MMP and TIMP multiplex antibody arrays. Panel B: Quantification of pixel intensity as a measure of protein expression from the culture media maintaining TTA + CSC 5 days after treatment and incubated with the human cytokine/chemokine antibody arrays. The results are presented as mean ± SE of three different determinations. *Significant difference (P < 0.05) in the treatment group compared to the untreated control group.